Invivo Hemostatic Effect of Ankaferd Blood Stopper in Rat Major Renal Trauma Model: Controlled Trial of Novel Hemostatic Agent

Ankaferd Bloodstopper (ABS) which is a medicinal product has been approved in the control of hemorrhage externally, dental surgery bleedings in Turkey to control the bleeding in renal trauma model was evaluated. Twelve Wistar rats were divided into two groups. Group I (GI),control, Group II (GII), study group. One cm(2) tissue was resected. ABS solution was applied to resected area in study group. Standard suture was applied to control group. Bleeding time, number of ABS, live condition were evaluated. Histopathologic evaluations were completed. Mean time of bleeding control was 3.2 (2.4-3.6) min in GII, no difference with Cl (p > 0.05). In GII, active hemostasis was provided. Mean number of ABS gout was 6.0 (5-8). Glomerular necrosis was detected with higher rate in GI compared with GII. Erythrocyte aggregation was confirmed in GII. Calcification was formed significantly in GI compared GII (p<0.05). ABS could be an effective agent to stop active major bleeding in renal trauma model.